J. Harris: Concerning the above charts: The first one, I piece together from several sources, almost daily, with some reports lagging a day or two. It takes me about an hour a day to put it together.
The second chart was in the Marshall News Messenger today and gives WEEKLY stats including fatalities.
The third chart is from the NYT and is a piece of a chart made to order for me. It arrives before the sun comes up daily and requires no effort on my part to assimilate the information — and it is accompanied by up-to-date, edited medical and Covid information in a readable form. You DO NOT HAVE TO BE A SUBSCRIBER to receive it by email or to make your own daily list of places that you’d like to see including virtually anywhere in the world. Were you to read this magnificent WORK, you could know ‘most everything that is going on in the Covid world ( and could localize your areas of interest as well). The Times does a great job with this constantly updated feature. I don’t know what to call it: a “work” or a “UNIT.” There are many dashboards, including some very good ones provided by The Texas Department of Health and Johns Hopkins, and from Oregon. However, in my opinion, this is the most useful Covid information that I receive, and these NYT folks are the only ones emailing me a personalized copy. Free. And, oh, you don’t see editorials.
From the NYT: More Good Vaccine News
A NEW “SUB-UNIT” VACCINE FROM CHINA
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
“…Although several COVID-19 vaccines have been developed so far, they will not be sufficient to meet the global demand. Development of a wider range of vaccines, with different mechanisms of action, could help control the spread of SARS-CoV-2 globally. We developed a protein subunit vaccine against COVID-19 using a dimeric form of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein as the antigen.
:… The [new] vaccine candidate, ZF2001, is a protein subunit vaccine that has advanced into phase 3 development.
“Compared with other vaccine candidates in clinical trials targeting mainly the whole virus or the S protein, ZF2001 targets the receptor-binding domain (RBD) of the SARS-CoV-2 S protein.
(J. Harris: The vaccine uses less antigenic material but has been found to stimulate antibody production and provide protection with tolerable side effects in a vaccine that might lend itself to mass production “cheaply”. It does not require extensive refrigeration. It is involved in large trials in China at this time.)
Routine asymptomatic testing for SARS-CoV-2 before travel can be an effective strategy to reduce passenger risk of infection during travel, although abbreviated quarantine with post-travel testing is probably needed to reduce population-level transmission due to importation of infection when travelling from a high to low incidence setting.
FROM HOPKINS CITATIONS
1. What it Will take to Vaccinate the World Against COVID-19 (Nature) A special report outlines the challenges — from unleashing the power of mRNA vaccines, to the battle for temporary intellectual-property relief. Within just a few months, pharmaceutical firms have produced hundreds of millions of doses of COVID-19 vaccine. But the world needs billions — and as fast as possible. Companies say they could make enough vaccines to immunize most of the world’s population by the end of 2021. But this doesn’t take into account political delays in distribution, such as countries imposing export controls — or that the overwhelming majority of doses are going to wealthier countries.
Incidence dynamics estimated based on wastewater data were found to better track the timing and shape of the reference infection peak compared to estimates based on confirmed cases. In contrast, case confirmations provided a better estimate of the subsequent decline in infections. Under a regime of high-test positivity rates, WBE thus provides critical information that is complementary to clinical data to monitor the pandemic trajectory.
CDC PRESS RELEASES:
1. First Mobile Vaccination Units in US to Open in Maryland The nation’s first federally operated mobile COVID-19 vaccination units will soon roll through eastern Maryland. The two mobile sites will provide access to COVID-19 vaccinations for thousands of Marylanders who live in remote or otherwise underserved areas in eight eastern Maryland counties. Targeted to people who are socially vulnerable or live in remote areas, appointments will be booked through the health department in the county of residence. (FEMA, 3/29/2021)
2. Connecticut First State to Open COVID-19 Vaccine Mobile Unit In the ongoing effort to bring the COVID vaccine to communities and people in socially vulnerable areas, Connecticut will open the country’s first Mobile Vaccination Unit (MVU) on March 29, 2021 at the Beardsley Zoo in Bridgeport, Connecticut. The MVU will travel throughout Connecticut for 60 days to reach populations in 17 communities. Destinations were targeted based on the CDC’s Social Vulnerability Index, US Census Bureau’s Community Resilience Estimates, low vaccine coverage, metrics and other barriers to vaccine access. The MVU will be used to complement ongoing efforts of local public health departments, health care providers, pharmacies, community and faith-based organizations, employers, private sector vaccinators and other federal resources. (FEMA, 3/26/2021)
LAST BUT NOT LEASED:
GIVE US YOUR FEEDBACK. CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.